Alcohol abstinence reduced #cirrhosis decompensation risk even in people with high portal pressure 1️⃣i ❤️good news 2️⃣study would have benefitted from peth 3️⃣👏👏first author Dr Hofer #livertwitter pubmed.ncbi.nlm.nih.gov/36481475/ CGH

Want to know more about selective internal radiation for liver cancer? 1. Study: can downstage! journals.lww.com/hepcomm/fullte… 2. Review: everything you need to know about Y-90 journals.lww.com/hepcomm/fullte… Both in Hepatology Communications

Keynote lecture: Ten years of improvement in the treatment of liver cancer #ESMOGI24 👉Amazing development, multiple 💊available in 2024 👉Redefining "cure" & role of LRT > early adaptation/switch 👉more to come: CAR-T cells, new💊, Proton Tx.. ESMO - Eur. Oncology #ESMOAmbassadors

1/2 Cholangiocarcinoma is a rare but serious liver cancer😕 🇫🇷 French experts have created guidelines to help doctors diagnose and treat it 🔬 Covers risk factors, screening, diagnosis, and treatment options 🔓 bit.ly/3S6mCzQ #livertwitter

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction - another piece of the puzzle by Claudia Angela M. Fulgenzi Surgery and Cancer UPO - Università jamanetwork.com/journals/jamao…

The relationship between sleep duration and some chronic conditions in ~7,000 AllofUsResearch participants Nature Medicine nature.com/articles/s4159…

#APPLE24 #HCC Professor Kudo 🇯🇵 takes us through the ultimate exercise in cross-trial comparison in 1L IO #HCC 📌 CM459, LEAP 002, IMbrave150, HIMALAYA, CM9DW ➡️ lenva better than sorafenib as control arm ➡️ anti-VEGF/IO - early OS separation ➡️ dual IO - better long term OS

⭕️Hepatic decompensation and mortality in HCC treated with atezo-beva HEPATOLOGY Journal 🚨Decompensation and disease progression are independent prognostic factors ➡️Decompensation HR: 19.04 (9.75-37.19) ➡️Progression HR: 9.91 (5.85-16.78) ✅Treatment of viral aetiology and

Evaluation of a delayed liver Tx strategy for HCC receiving bridging therapy Journal of Hepatology doi.org/10.1016/j.jhep… 🔎DELTA-HCC study 👉20% of LTx candidates w/ single curative treated tumors 👉LT can be safely delayed in these pts 🧐supports redirection of spared organs ESMO - Eur. Oncology

ORIGINAL ARTICLE Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment Celsa et al. ​​#LiverX tinyurl.com/549kxxae

Alcohol is extra toxic to the liver after bariatric surgery because of decreased metabolism of ethanol by the bypassed stomach Screen for binge drinking in people who are undergoing or have received bariatric surgery journals.lww.com/hepcomm/fullte…

This is actually what I have been seeing along these years of A+B use. Agreed fully

1) Our manuscript entitled « Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments” was recently released in Gut gut.bmj.com/content/early/… Claudia Campani Centre de Recherche des Cordeliers Sandra Rebouissou GUTJournal_BMJ Theo Hirsch Sandrine Imbeaud

1) Our new manuscript « Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies” was just published in JHEP Reports with Claudia Campani and Dimitrios Pallas jhep-reports.eu/article/S2589-…

📑 Noninvasive predictors of clinically significant portal hypertension in #NASH cirrhosis❗️ 1️⃣ANTICIPATE (TE+Plt) & ANTICIPATE-NASH (+BMI) predict CSPH 2️⃣New model, ⭐️ FIB4+ (FIB4+Albumin), also predicts CSPH and does not require elastography❕ journals.lww.com/hepcomm/fullte…

People with PCOS have a higher risk of type 2 diabetes, hypertension, hepatocellular carcinoma, and depression or anxiety compared with controls. They also have a higher risk for cardiovascular disease, hepatic steatosis, and hepatic fibro-inflammation. academic.oup.com/jcem/advance-a…

📢Check our September issue ‼️ 💥Featured article: Comparison of non-contrast abbreviated MRI and ultrasound as surveillance modalities for HCC🔗bit.ly/3yJhR8Z Full issue here👉bit.ly/36khmDF #LiverTwitter Paolo Angeli EASL Education EASLnews

New article in Journal of Liver Cancer Evolving trends in treatment patterns for #HCC in Korea 🇰🇷 from 2008 to 2022: a nationwide population-based study Han JW, Sohn W et al.

📑 #NASH is the most common indication for LT among the elderly❗️ 1️⃣ Proportion of LT occurring in patients age 65+ years 📈 2️⃣ NASH etiology in more than 1 in 3 listings with ⬆️ prevalence over time #LiverTwitter #MASLD #OpenAccess journals.lww.com/hepcomm/fullte…

From JAMA: JAMA Clinical Guidelines Synopsis: the 2023 American Association for the Study of Liver Diseases practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. ja.ma/3AJzUfJ